J&J's first-quarter profit beats estimates even as Stelara sales fall more than expected

Strong demand for Darzalex and Tremfya more than offset a steep falloff in sales of Stelara, indicating a mixed but resilient underlying performance in the company's healthcare portfolio. The article points to offsetting product trends rather than a clear positive or negative surprise, with no specific revenue or earnings figures provided. Market impact is likely limited unless accompanied by full quarterly results or guidance.

Analysis

Strong demand for Darzalex and Tremfya more than offset a steep falloff in sales of Stelara, indicating a mixed but resilient underlying performance in the company's healthcare portfolio. The article points to offsetting product trends rather than a clear positive or negative surprise, with no specific revenue or earnings figures provided. Market impact is likely limited unless accompanied by full quarterly results or guidance.